The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study
Abstract
PURPOSE: To compare the effects of the two novel, potent, nonsteroidal aromatase inhibitors anastrozole and letrozole on total-body aromatization and plasma estrogen levels. PATIENTS AND METHODS: Twelve postmenopausal women with estrogen receptor–positive, metastatic breast cancer were treated with anastrozole 1 mg orally (PO) and letrozole 2.5 mg PO once daily, each given for a time interval of 6 weeks in a randomized sequence. Total-body aromatization was determined before treatment and at the end of each treatment period using a dual-label isotopic technique involving isolation of the metabolites with high-performance liquid chromatography. Plasma levels of estrone (E 1 ), estradiol (E 2 ), and estrone sulfate (E 1 S) were determined in samples obtained before each injection using highly sensitive radioimmunoassays. RESULTS: Pretreatment aromatase levels ranged from 1.68% to 4.27%. On-treatment levels of aromatase were detectable in 11 of 12 patients during treatment with anastrozole (mean percentage inhibition in the whole group, 97.3%) but in none of the 12 patients during treatment with letrozole (> 99.1% suppression in all patients; Wilcoxon, P = .0022, comparing the two drug regimens). Treatment with anastrozole suppressed plasma levels of E 1 , E 2 , and E 1 S by a mean of 81.0%, 84.9%, and 93.5%, respectrively, whereas treatment with letrozole caused a corresponding decrease of 84.3%, 87.8% and 98.0%, respectively. The suppression of E 1 and E 1 S was found to be significantly better during treatment with letrozole compared with anastrozole (P = .019 and .0037, respectively). CONCLUSION: This study revealed letrozole (2.5 mg once daily) to be a more potent suppressor of total-body aromatization and plasma estrogen levels compared with anastrozole (1 mg once daily) in postmenopausal women with metastatic breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Estrogen excess in turn has been associated with premature closure of the epiphyses, gynecomastia and low gonadotropin and testosterone levels.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [25]
In the citing paper
“Estrogen excess in turn has been associated with premature closure of the epiphyses, gynecomastia and low gonadotropin and testosterone levels.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [25]
In the citing paper
“Aromatase inhibitors effectively delay epiphysial maturation in boys and improve testosterone levels in adult men”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [25]
In the citing paper
“Estrogen excess in turn has been associated with premature closure of the epiphyses, gynecomastia and low gonadotropin and testosterone levels.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [25]
In the citing paper
“Estrogen excess in turn has been associated with premature closure of the epiphyses, gynecomastia and low gonadotropin and testosterone levels.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [25]
In the citing paper
“This approach proved successful in rare conditions such as the aromatase-excess syndrome [25] and high estrogen levels due to Sertoli cell tumors in boys with Peutz-Jeghers syndrome [55].”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [25]
In the citing paper
“Estrogens are essential for epiphysial maturation in boys.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [25]
Citations
Cites
Dombernowsky, P., Smith, I. E., Falkson, G., Leonard, R. C., Panasci, L., Joaquim Bellmunt, B., Bezwoda, W. R., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 629
Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Červek, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1399 · Cited by 520
Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., BLOMQVIST, C. P., Vogel, C. L., EIERMANN, W., Wolter, J. M., Steinberg, M., Webster, A., et al. (1998) · PubMed · Cited by 417
Buzdar, A., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C., Vogel, C. L., Eiermann, W., Wolter, J. M., Azab, M., Webster, A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2000 · Cited by 406
Geisler, J., King, N. C., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P. O., & Lønning, P. E. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.531 · Cited by 332
Self-citationLønning, P. E., Bajetta, E., Murray, R., Tubiana-Hulin, M., Eisenberg, P. D., Mickiewicz, E., Celio, L., Pitt, P., Mita, M. M., Aaronson, N. K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2234 · Cited by 316
Self-citationGeisler, J., King, N. C., Anker, G. B., Ornati, G., di Salle, E., Lønning, P. E., & Dowsett, M. (1998) · PubMed · Cited by 314
Self-citationEstrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
Masamura, S., Santner, S. J., Heitjan, D. F., & Santen, R. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.10.7559875 · Cited by 307
Gershanovich, M., Chaudri, H. A., Campos, D., Lurie, H., Bonaventura, A., Jeffrey, M., Buzzi, F., Bodrogi, I., Ludwig, H., Reichardt, P., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008226721932 · Cited by 255
Dowsett, M., Goss, P. E., Powles, T., Hutchinson, G., Brodie, A. M., Jeffcoate, S. L., & Coombes, R. C. (1987) · PubMed · Cited by 238
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–606 of 606
Lee, S. K., Choi, H. R., Kang, D., Jang, Y., Ryu, S., Lee, J. E., Nam, S. J., Kim, S. W., Chae, B. J., Ryu, J. M., et al. (2026) · The Breast · doi:10.1016/j.breast.2026.104947
Ruthenium-catalyzed strategies for the synthesis of bioactive heterocycles
Guduru, M. K. P., Padavala, R., Sarkar, R., & Joarder, D. D. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1953749
Robarge, J. (2014) · IUScholarWorks (Indiana University) · doi:10.7912/c2/304
Aromatase Inhibitors as Chemopreventives of Breast Cancer
Dowsett, M., & Garber, J. E. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-767-3_15
Self-citation
Metadata
- Authors
- Geisler, J., Haynes, B., Anker, G., Dowsett, M., & Lønning, P. E.
- Affiliations
- Haukeland University Hospital (NO)
- Venue
- Journal of Clinical Oncology
- Published
- 2002-02-01
- Volume
- 20
- Issue
- 3
- Pages
- 751-757
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2145819414
- Cited by
- 604
- References
- 37
- Citations by year
- 2026: 8 · 2025: 3 · 2024: 8 · 2023: 15 · 2022: 10 · 2021: 11 · 2020: 14 · 2019: 14 · 2018: 12 · 2017: 18 · 2016: 25 · 2015: 23 · 2014: 26 · 2013: 22 · 2012: 16
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- letrozole, anastrozole, aromatase inhibitors, aromatization, plasma estrogen, estrone, estradiol, estrone sulfate, metastatic breast cancer, postmenopausal women, estrogen receptor-positive breast cancer, aromatase inhibition
- MeSH terms
- Letrozole, Anastrozole, Aged, Antineoplastic Agents, Aromatase, Breast Neoplasms, Chromatography, High Pressure Liquid, Enzyme Inhibitors, Estradiol, Estrogens, Estrone, Female, Humans, Middle Aged, Nitriles, Radioimmunoassay, Triazoles, Postmenopause, Cross-Over Studies, Antineoplastic Agents, Hormonal, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
